What are the latest updates to small cell lung cancer treatment?

Latest Updates in Small Cell Lung Cancer Treatment

The most significant recent advances in SCLC treatment are the FDA approval of tarlatamab for relapsed disease and the establishment of consolidation durvalumab as standard of care for limited-stage SCLC after chemoradiotherapy. 1

Limited-Stage SCLC: Consolidation Immunotherapy

Patients with LS-SCLC who complete concurrent chemoradiotherapy without disease progression should receive consolidation durvalumab for up to 2 years (unless contraindications to immunotherapy exist). 1

Key Evidence from ADRIATIC Trial:

• Median overall survival improved from 33.4 months (placebo) to 55.9 months (durvalumab) - nearly a 2-year improvement 1
• 24-month OS rates: 68% vs 58.5% 1
• 36-month OS rates: 56.5% vs 47.6% 1
• Median PFS improved from 9.2 months to 16.6 months (HR 0.76) 1
• Treatment-related grade 3-4 adverse events occurred in only 8.8% of durvalumab patients 1

This represents a paradigm shift, as the 2-year OS improvement with durvalumab consolidation is substantial compared to historical chemoradiotherapy-alone outcomes. 1

Special Population:

Patients with poor performance status (ECOG PS 3-4) who improve after chemoradiotherapy may also be offered consolidation durvalumab, though this carries a conditional recommendation based on lower quality evidence. 1

Relapsed/Refractory SCLC: Tarlatamab as New Standard

Tarlatamab is now a preferred agent alongside topotecan and lurbinectedin for relapsed SCLC, representing the first novel mechanism approved in this setting in years. 1

Tarlatamab Mechanism and Efficacy:

• Bispecific T-cell engager targeting DLL3 (on SCLC cells) and CD3 (on T cells) to stimulate immune-mediated tumor killing 1
• Overall response rate: 40% with median duration of response of 9.7 months - substantially longer than other agents 1
• Response rate in platinum-resistant disease: 52% 1
• Response rate in platinum-sensitive disease: 31% 1
• Median PFS: 4.9 months 1
• 9-month OS rate: 68% 1

The duration of response exceeding 9 months with tarlatamab is notably superior to topotecan or other chemotherapy agents, though direct head-to-head comparisons are pending (DeLLphi-304 trial ongoing). 1

Tarlatamab Dosing and Safety Protocol:

Recommended regimen: 1

• Day 1 of cycle 1: 1 mg IV (step-up dose)
• Days 8 and 15 of cycle 1: 10 mg IV
• Thereafter: 10 mg IV every 2 weeks until progression or unacceptable toxicity

Critical safety monitoring: 1

• Mandatory 24-hour inpatient monitoring after first two doses (days 1 and 8 of cycle 1) due to cytokine release syndrome (CRS) risk
• CRS occurred in 51% of patients (mostly grade 1-2; only 1% grade 3) 1
• CRS symptoms: fever (97%), hypotension (20%), hypoxia (17%) 1
• Median CRS onset: 13 hours; median duration: 4 days 1
• Nearly all CRS events occur during first cycle 1
• Immune effector cell-associated neurotoxicity syndrome (ICANS) in 8% (all grade 1-2) 1

Patient Selection for Tarlatamab:

Eligible patients: 1

• Disease progression after ≥2 prior systemic regimens (including platinum-based)
• ECOG PS 0-1
• Asymptomatic, previously treated, stable brain metastases allowed

Exclusion criteria: 1

• Interstitial lung disease or active pneumonitis
• History of severe immune-related adverse events
• Grade ≥2 pneumonitis from prior immunotherapy

Treatment Algorithm for Relapsed SCLC

Chemotherapy-Free Interval <90 Days (Platinum-Resistant):

Single-agent systemic therapy is preferred over multiagent regimens due to better risk-benefit balance. 1

Preferred agents (all equally recommended): 1

• Tarlatamab
• Lurbinectedin
• Topotecan

Chemotherapy-Free Interval ≥90 Days (Platinum-Sensitive):

Either rechallenge with platinum-based regimen OR single-agent therapy (topotecan, lurbinectedin, or tarlatamab) may be offered. 1

Extensive-Stage SCLC: First-Line Standard Remains Chemoimmunotherapy

While not a new update, first-line treatment with platinum-etoposide plus immunotherapy (atezolizumab or durvalumab) followed by maintenance immunotherapy remains standard of care for ES-SCLC without contraindications to immunotherapy. 1

Key Clinical Pitfalls and Caveats

Sequencing uncertainty: There are currently no data comparing tarlatamab, lurbinectedin, and topotecan head-to-head, so optimal sequencing remains unknown pending the DeLLphi-304 trial results. 1

Tarlatamab monitoring requirements: The mandatory 24-hour inpatient observation for the first two doses represents a significant logistical consideration that must be planned for. 1

Durvalumab consolidation timing: This should only be offered to patients who complete chemoradiotherapy without disease progression - not for those with progressive disease. 1

Performance status considerations: While tarlatamab trials only included PS 0-1 patients, durvalumab consolidation may be considered in PS 3-4 patients who improve after initial therapy, though evidence quality is lower. 1